Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany (Q34217022)

31 July 2017

title

Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany (English)

1 reference

31 July 2017

0 references

1 reference

Freimut H Schilling

1 reference

31 July 2017

Claudia Spix

1 reference

31 July 2017

Frank Berthold

1 reference

31 July 2017

Rudolf Erttmann

1 reference

31 July 2017

Johannes Sander

1 reference

31 July 2017

Joern Treuner

1 reference

31 July 2017

Joerg Michaelis

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

31 July 2017

1 reference

31 July 2017

volume

197

1 reference

31 July 2017

issue

1-2

1 reference

31 July 2017

page(s)

19-28

1 reference

Neuroblastoma in Europe: differences in the pattern of disease in the UK. SENSE. Study group for the Evaluation of Neuroblastoma Screening in Europe

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian Cooperative Group on Neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Survival of children with neuroblastoma. time trends and regional differences in Europe, 1978--1992

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Neuroblastoma: current drug therapy recommendations as part of the total treatment approach

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Neuroblastoma mass screening: The arguments for and against

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Determination of urinary homovanillic and vanillylmandelic acids from dried filter paper samples: assessment of potential methods for neuroblastoma screening.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

A population-based study of the usefulness of screening for neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Neuroblastoma Screening at One Year of Age

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Randomized controlled trials in population-based intervention studies are not always feasible

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

A simple approximation for calculating sample sizes for comparing independent proportions

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

An improved approximate formula for calculating sample sizes for comparing two binomial distributions

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Which cases are found and missed by neuroblastoma screening at 1 year? Results from the 1992 to 1995 study in three Federal States of Germany

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Advances in Record-Linkage Methodology as Applied to Matching the 1985 Census of Tampa, Florida

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Special pattern of widespread neuroblastoma with a favourable prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Spontaneous regression of localized neuroblastoma detected by mass screening

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Instrumental variables when evaluating screening trials: estimating the benefit of detecting cancer by screening.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Are increasing 5-year survival rates evidence of success against cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Childhood malignancies in Germany—methods and results of a nationwide registry

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

History and current status of neuroblastoma screening in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Decrease in childhood neuroblastoma death in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Mass screening for neuroblastoma and mortality in birth cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Mass screening for neuroblastoma at 6 months of age: difficult to justify

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Effects of mass screening on age-specific incidence of neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status. Study Group of Japan for Treatment of Advanced Neuroblastoma, Tokyo, Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Problems of neuroblastoma screening for 6 month olds and results of second screening for 18 month olds

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Mass screening for neuroblastoma targeting children age 14 months in Sapporo City: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Screening of infants and mortality due to neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Molecular biology of neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2803%2900077-6

7 January 2021

10.1016/S0304-3835(03)00077-6

Identifiers

DOI

1 reference

31 July 2017

1 reference